Key result
Pulmonary embolism in lung cancer linked to ~6 months shorter median overall survival.
Why the study?
Pulmonary embolism is a potentially fatal complication with increased morbidity and mortality in cancer patients, making early diagnosis important, but the risk factors of lung cancer complicated with PE needed exploration.
What are the independent risk factors for pulmonary embolism in patients with lung cancer?
Cohort (n=100)
What are the independent risk factors for pulmonary embolism in patients with lung cancer?
In lung cancer patients, high D-dimer, chemotherapy, DVT, advanced stage, and adenocarcinoma are independent risk factors for developing pulmonary embolism, which significantly worsens survival.
Answers are grounded in this paper and cite their sources.
PE-associated survival decrement in lung cancer supports risk stratification; leaves open whether prophylaxis improves outcomes.
INTRODUCTION: Pulmonary embolism (PE) is a potentially fatal complication and its morbidity together with fatalness will further increase when in patients with malignant tumors. Fast and accurate early diagnosis of PE thus seems considerably important. OBJECTIVE: To explore the risk factors of lung cancer complicated with PE. MATERIALS AND METHODS: A retrospective cohort study consisted of 40 lung cancer patients with PE (PE group) and 60 lung cancer patients without PE (non-PE group) were analyzed. RESULTS: ) in PE group was lower than that in non-PE group (P < 0.05). Carcinoembryonic antigen (CEA) level between two groups also exhibited statistical difference (P < 0.05). Those lung adenocarcinoma patients with stages III and IV tumor, coupled with deep venous thrombosis (DVT), having experienced bevacizumab treatment or platinum-based chemotherapy more likely suffered from PE (P < 0.05). The multivariate analysis revealed that high D-dimer, chemotherapy, DVT, stages III to IV, adenocarcinoma were independent risk factors associated with PE (P < 0.05). The overall survival time of patients in case group was significantly shorter than that in the control group with a median survival duration being 10.5 months (95%CI, 8.95-12.05) and 16.8 months (95%CI, 14.62-18.98), respectively, (P < 0.01). CONCLUSIONS: High D-dimer, chemotherapy, DVT, stages III to IV and adenocarcinoma might have a positive correlation with PE, meanwhile, PE always predicted a poor prognosis in lung cancer patients.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2020) conducted a cohort in Lung cancer complicated with pulmonary embolism (n=100). Pulmonary embolism vs. No pulmonary embolism was evaluated on Overall survival time (p=<0.01). Pulmonary embolism in lung cancer patients was associated with significantly shorter median overall survival compared to those without pulmonary embolism (10.5 vs 16.8 months; P<0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: